EA202090693A1 - Новый ингибитор mek для лечения вирусных и бактериальных инфекций - Google Patents

Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Info

Publication number
EA202090693A1
EA202090693A1 EA202090693A EA202090693A EA202090693A1 EA 202090693 A1 EA202090693 A1 EA 202090693A1 EA 202090693 A EA202090693 A EA 202090693A EA 202090693 A EA202090693 A EA 202090693A EA 202090693 A1 EA202090693 A1 EA 202090693A1
Authority
EA
Eurasian Patent Office
Prior art keywords
viral
treatment
bacterial infections
mek inhibitor
infection
Prior art date
Application number
EA202090693A
Other languages
English (en)
Inventor
Штефан Людвиг
Оливер Планц
Original Assignee
Атрива Терапьютикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Атрива Терапьютикс Гмбх filed Critical Атрива Терапьютикс Гмбх
Publication of EA202090693A1 publication Critical patent/EA202090693A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение относится к PD-0184264 для применения в способе профилактики и/или лечения коинфекции, включающей бактериальную инфекцию и вирусную инфекцию гриппа или только вирусную или бактериальную инфекцию. Также предложены композиции, содержащие такие ингибиторы, для применения в профилактике и/или лечении коинфекции, включающей бактериальную инфекцию и вирусную инфекцию гриппа или только бактериальную или вирусную инфекцию.
EA202090693A 2017-10-17 2018-10-17 Новый ингибитор mek для лечения вирусных и бактериальных инфекций EA202090693A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
EA202090693A1 true EA202090693A1 (ru) 2020-10-19

Family

ID=60484427

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090693A EA202090693A1 (ru) 2017-10-17 2018-10-17 Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Country Status (21)

Country Link
US (1) US11903917B2 (ru)
EP (2) EP3697405B1 (ru)
JP (2) JP7227967B2 (ru)
KR (1) KR20200072499A (ru)
CN (1) CN111479566A (ru)
AU (1) AU2018351475A1 (ru)
BR (1) BR112020007442A2 (ru)
CA (1) CA3078424A1 (ru)
CY (1) CY1124507T1 (ru)
DK (1) DK3697405T3 (ru)
EA (1) EA202090693A1 (ru)
ES (1) ES2883639T3 (ru)
HR (1) HRP20211252T1 (ru)
HU (1) HUE055738T2 (ru)
LT (1) LT3697405T (ru)
MX (2) MX2020003473A (ru)
PL (1) PL3697405T3 (ru)
PT (1) PT3697405T (ru)
SI (1) SI3697405T1 (ru)
WO (1) WO2019076947A1 (ru)
ZA (1) ZA202002069B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114667138A (zh) * 2019-08-27 2022-06-24 归属疗法有限公司 Mek抑制剂与帽状结构依赖型核酸内切酶抑制剂的组合
BR112022005896A2 (pt) 2019-10-08 2022-06-28 Atriva Therapeutics Gmbh Inibidores da mek para o tratamento de infecções causadas por hantavírus
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP1140067A1 (en) * 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
JP2003504400A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
CN105101999B (zh) * 2012-10-08 2018-07-17 归属疗法有限公司 用在病毒性疾病的治疗中的mek抑制剂
BR112016026556A8 (pt) 2014-05-16 2021-07-06 Atriva Therapeutics Gmbh inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção
BR112022005896A2 (pt) 2019-10-08 2022-06-28 Atriva Therapeutics Gmbh Inibidores da mek para o tratamento de infecções causadas por hantavírus
EP3912623A1 (en) 2020-05-20 2021-11-24 Atriva Therapeutics GmbH Mek-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
HUE055738T2 (hu) 2021-12-28
BR112020007442A2 (pt) 2020-10-27
US20200289445A1 (en) 2020-09-17
AU2018351475A1 (en) 2020-04-30
JP7227967B2 (ja) 2023-02-22
LT3697405T (lt) 2021-10-25
CN111479566A (zh) 2020-07-31
PT3697405T (pt) 2021-08-27
EP3973960A1 (en) 2022-03-30
KR20200072499A (ko) 2020-06-22
US11903917B2 (en) 2024-02-20
SI3697405T1 (sl) 2021-11-30
CA3078424A1 (en) 2019-04-25
MX2022016066A (es) 2023-02-02
JP2020537659A (ja) 2020-12-24
EP3697405B1 (en) 2021-07-14
ZA202002069B (en) 2021-10-27
EP3697405A1 (en) 2020-08-26
PL3697405T3 (pl) 2021-12-13
ES2883639T3 (es) 2021-12-09
WO2019076947A1 (en) 2019-04-25
JP2023058631A (ja) 2023-04-25
MX2020003473A (es) 2020-10-01
HRP20211252T1 (hr) 2021-11-12
DK3697405T3 (da) 2021-08-23
CY1124507T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
EA201692303A1 (ru) Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
PH12017500207A1 (en) Indoles for use in influenza virus infection
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA202091849A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
EA201790778A1 (ru) Фармацевтические композиции длительного действия от гепатита с